Tryp Therapeutics Gears Up for Merger Completion with Exopharm, Announces Trading Halt

Tryp Therapeutics, Inc. has announced that Exopharm Limited shareholders have approved a plan of arrangement, paving the way for the anticipated merger. This approval satisfies key conditions of the deal, with final confirmation pending from the Australian Securities Exchange expected by April 30, 2024. The merger is projected to finalize around May 1, 2024, with the new entity, Tryptamine Therapeutics Limited, expected to list on the ASX with the ticker "TYP" by May 15, 2024.

In preparation for the merger's finalization, Tryp Therapeutics has initiated a voluntary halt on trading of its shares on the Canadian Securities Exchange and the OTCQB Venture Market starting April 29, 2024. Post-merger, Tryp’s shares will be delisted from these exchanges. Tryp shareholders are required to submit their share certificates along with a signed letter of transmittal to Computershare Investor Services Inc. to receive merger considerations.